Rocket Pharmaceuticals, Inc Sustainability Profile
Rocket Pharmaceuticals, Inc., a leading player in the biotechnology sector, is headquartered in the United States. Founded in 2015, the company has rapidly established itself as a pioneer in gene therapy, focusing on innovative treatments for rare genetic diseases. With a strong operational presence in key regions, Rocket Pharmaceuticals is dedicated to developing transformative therapies that address significant unmet medical needs. The company’s core offerings include advanced gene therapies designed to treat conditions such as Fanconi Anaemia and other inherited disorders. What sets Rocket apart is its commitment to harnessing cutting-edge technology to create unique, patient-centric solutions. Recognised for its robust pipeline and strategic partnerships, Rocket Pharmaceuticals continues to solidify its position in the market, aiming to revolutionise the landscape of genetic medicine.
DitchCarbon Score
How does Rocket Pharmaceuticals, Inc's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Rocket Pharmaceuticals, Inc's score of 30 is lower than 50% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Rocket Pharmaceuticals, Inc's reported carbon emissions
In 2023, Rocket Pharmaceuticals, Inc. reported total carbon emissions of approximately 2,309,200 kg CO2e, comprising 418,200 kg CO2e from Scope 1 emissions and 1,889,000 kg CO2e from Scope 2 emissions. This marks a reduction in emissions from 2022, where the company recorded about 2,367,000 kg CO2e, with Scope 1 emissions at 597,000 kg CO2e and Scope 2 emissions at 1,770,000 kg CO2e. The company has not disclosed any Scope 3 emissions data, indicating a potential area for future reporting and improvement. Notably, Rocket Pharmaceuticals has not set specific reduction targets or initiatives under the Science Based Targets initiative (SBTi) or other climate pledges, which suggests that while they are tracking emissions, they may not yet have formalised commitments to reduce them. Overall, Rocket Pharmaceuticals is actively monitoring its carbon footprint, with a focus on Scope 1 and 2 emissions, but further transparency and commitment to reduction targets could enhance its climate strategy.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | |
|---|---|---|---|
| Scope 1 | 597,000 | 000,000 | 000,000 |
| Scope 2 | 1,689,000 | 0,000,000 | 0,000,000 |
| Scope 3 | - | - | - |
How Carbon Intensive is Rocket Pharmaceuticals, Inc's Industry?
How Carbon Intensive is Rocket Pharmaceuticals, Inc's Location?
Rocket Pharmaceuticals, Inc's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Rocket Pharmaceuticals, Inc has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
